Brief: Arbutus Doses First Subject In Phase 1 Clinical Trial With Its Oral RNA Destabilizer

Arbutus Biopharma

16/03/2023 11:45

March 16 (Reuters) - Arbutus Biopharma Corp  ABUS.O :
    * ARBUTUS DOSES FIRST SUBJECT IN PHASE 1 CLINICAL TRIAL WITH
ITS
ORAL RNA DESTABILIZER, AB-161
    * ARBUTUS BIOPHARMA CORP - INITIAL DATA EXPECTED IN SECOND
HALF OF
2023

Source text for Eikon:  ID:nGNXt9NXy 
Further company coverage:  ABUS.O 

 ((Reuters.Briefs@thomsonreuters.com;))